BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China flag China · Delayed Price · Currency is CNY
35.81
+1.45 (4.22%)
At close: Sep 30, 2026

SHA:688166 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,3281,1901,2481,1611,0131,050
Other Revenue
36.6534.1434.2718.344.042.25
1,3641,2241,2831,1801,0171,052
Revenue Growth
17.38%-4.59%8.73%15.94%-3.33%34.00%
Cost of Revenue
643.9615.41560.51542.9390.95470.07
Gross Profit
720.39608.23722.04636.61626.38582.34
Selling, General & Admin
210.67232.53210.87180.46184.98145.56
Research & Development
337.71304.95297.45248.59207.02173.29
Other Operating Expenses
6.72-0.491.39-1.595.224.22
Operating Expenses
602.33556.67521.27428.37395333.18
Operating Income
118.0651.56200.76208.24231.38249.16
Interest Expense
-72.58-62.96-52.44-44.42-23.71-9.7
Interest & Investment Income
3.945.5510.9617.996.210.14
Currency Exchange Gain (Loss)
-7.566.091.922.612.994.63
Other Non Operating Income (Expenses)
-1.09-2.07-2.14-1.88-2.17-1.77
EBT Excluding Unusual Items
40.78-1.83159.07182.54224.68252.46
Impairment of Goodwill
-3.12-3.12-4.38---
Gain (Loss) on Sale of Investments
13.5-5.54-17.33-15.26-3.390.79
Gain (Loss) on Sale of Assets
-0.33-0.5-0.15-0.25-0.01-0.26
Other Unusual Items
29.124.8919.9921.7420.934.47
Pretax Income
79.9313.91157.2188.77242.21257.46
Income Tax Expense
-19.85-23.0515.9415.3530.7819.9
Earnings From Continuing Operations
99.7836.95141.26173.42211.43237.56
Minority Interest in Earnings
-3.5117.5647.929.0428.26.39
Net Income
96.2754.51189.17202.47239.62243.95
Net Income to Common
96.2754.51189.17202.47239.62243.95
Net Income Growth
-3.70%-71.18%-6.57%-15.51%-1.77%43.60%
Shares Outstanding (Basic)
415419420422413407
Shares Outstanding (Diluted)
415419420422413407
Shares Change
-1.69%-0.24%-0.34%2.10%1.61%-1.87%
EPS (Basic)
0.230.130.450.480.580.60
EPS (Diluted)
0.230.130.450.480.580.60
EPS Growth
-2.04%-71.11%-6.25%-17.24%-3.33%46.34%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-15.35-128.22-11.64-209-415.47-733.59
Free Cash Flow Per Share
-0.04-0.31-0.03-0.49-1.01-1.80
Dividend Per Share
0.0160.0160.0960.0960.1140.120
Dividend Growth
-83.33%-83.33%0%-15.79%-5.00%42.86%
Gross Margin
52.80%49.71%56.30%53.97%61.57%55.33%
Operating Margin
8.65%4.21%15.65%17.66%22.74%23.67%
Profit Margin
7.06%4.46%14.75%17.16%23.55%23.18%
Free Cash Flow Margin
-1.13%-10.48%-0.91%-17.72%-40.84%-69.71%
EBITDA
267.96195.13298.05275.07271.03283.34
EBITDA Margin
19.64%15.95%23.24%23.32%26.64%26.92%
D&A For EBITDA
149.89143.5797.2866.8339.6534.18
EBIT
118.0651.56200.76208.24231.38249.16
EBIT Margin
8.65%4.21%15.65%17.66%22.74%23.67%
Effective Tax Rate
--10.14%8.13%12.71%7.73%
Revenue as Reported
1,3641,2241,2831,1801,0171,052
Advertising Expenses
-1.692.28-0.521.01